$ENGN
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-GuΓ©rin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Healthcare
Sector
Biotechnology
Industry
Ronald H. W. Cooper
CEO
56
Employees
$1.92
Current Price
$510.41M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 1 | 1 | $10,050.94 | 5,102 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 1 | 1 | $10,050.94 | 5,102 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 1 | $10,050.94 | 5,102 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 1 | 1 | $10,050.94 | 5,102 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 1 | 1 | $10,050.94 | 5,102 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months β create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | Grossman William Director | Purchase | 5,102 | $1.97 | $10,050.94 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.43
Actual-$0.47
Miss
Revenue
EstimatedN/A
ActualN/A
2 more earnings records available β create a free account to see 12 months of history